These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 35829744)

  • 41. The prognostic value of TP53 and its correlation with EGFR mutation in advanced non-small cell lung cancer, an analysis based on cBioPortal data base.
    Jiao XD; Qin BD; You P; Cai J; Zang YS
    Lung Cancer; 2018 Sep; 123():70-75. PubMed ID: 30089598
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib.
    Wu KL; Tsai MJ; Yang CJ; Chang WA; Hung JY; Yen CJ; Shen CH; Kuo TY; Lee JY; Chou SH; Liu TC; Chong IW; Huang MS
    Lung Cancer; 2015 May; 88(2):187-94. PubMed ID: 25747806
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Prognostic Role of PORT and EGFR Mutation Status in Completely Resected Stage IIIA/N2 Non-Small Cell Lung Cancer Patients with Postoperative Chemotherapy.
    Yang H; Wang K; Li S; Li Y; Yuan L
    Pathol Oncol Res; 2021; 27():1609898. PubMed ID: 34447289
    [No Abstract]   [Full Text] [Related]  

  • 44. A systematic analysis of the resistance and sensitivity of HER2YVMA receptor tyrosine kinase mutant to tyrosine kinase inhibitors in HER2-positive lung cancer.
    Shen X; Chen B; Ma Z; Xie B; Cao X; Yang T; Zhao Y; Qin J; Li J; Cao F; Chen X
    J Recept Signal Transduct Res; 2016; 36(1):89-97. PubMed ID: 26391018
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Outcomes of chemotherapies and HER2 directed therapies in advanced HER2-mutant lung cancers.
    Eng J; Hsu M; Chaft JE; Kris MG; Arcila ME; Li BT
    Lung Cancer; 2016 Sep; 99():53-6. PubMed ID: 27565914
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Relationship between EGFR and KRAS mutations and prognosis in Chinese patients with non-small cell lung cancer: a mutation analysis with real-time polymerase chain reaction using scorpion amplification refractory mutation system].
    Gao J; Chen JQ; Zhang L; Liang ZY
    Zhonghua Bing Li Xue Za Zhi; 2012 Oct; 41(10):652-6. PubMed ID: 23302304
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical study on long-term overall survival of advanced non-small-cell lung cancer patients treated with Chinese medicine and Western medicine.
    Chen YZ; Feng XB; Li ZD; Zheng WX; Sun H; Li PP
    Chin J Integr Med; 2014 Mar; 20(3):179-83. PubMed ID: 24615210
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Subtypes of EGFR- and HER2-Mutant Metastatic NSCLC Influence Response to Immune Checkpoint Inhibitors.
    Lau SCM; Fares AF; Le LW; Mackay KM; Soberano S; Chan SW; Smith E; Ryan M; Tsao MS; Bradbury PA; Pal P; Shepherd FA; Liu G; Leighl NB; Sacher AG
    Clin Lung Cancer; 2021 Jul; 22(4):253-259. PubMed ID: 33582070
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prognostic analysis of patients with non-small cell lung cancer harboring exon 19 or 21 mutation in the epidermal growth factor gene and brain metastases.
    Wang J; Liu Z; Pang Q; Zhang T; Chen X; Er P; Wang Y; Wang P; Wang J
    BMC Cancer; 2020 Sep; 20(1):837. PubMed ID: 32883221
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Association of tumor mutation burden and epidermal growth factor receptor inhibitor history with survival in patients with metastatic stage III/IV non-small-cell lung cancer: A retrospective study.
    Lan Y; Zhou S; Feng W; Qiao Y; Du X; Li F
    Clinics (Sao Paulo); 2021; 76():e2251. PubMed ID: 33787673
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prognostic value analysis of mutational and clinicopathological factors in non-small cell lung cancer.
    Li C; Hao L; Li Y; Wang S; Chen H; Zhang L; Ke B; Yin Y; Suo H; Sun B; Zhang B; Wang C
    PLoS One; 2014; 9(9):e107276. PubMed ID: 25198510
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Genetic alterations of driver genes as independent prognostic factors for disease-free survival in patients with resected non-small cell lung cancer.
    Ono A; Isaka M; Serizawa M; Omae K; Kojima H; Nakashima K; Omori S; Wakuda K; Kenmotsu H; Naito T; Murakami H; Urakami K; Nagashima T; Sugino T; Kusuhara M; Takahashi T; Yamaguchi K; Ohde Y
    Lung Cancer; 2019 Feb; 128():152-157. PubMed ID: 30553548
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Targeting
    Han H; Li S; Chen T; Fitzgerald M; Liu S; Peng C; Tang KH; Cao S; Chouitar J; Wu J; Peng D; Deng J; Gao Z; Baker TE; Li F; Zhang H; Pan Y; Ding H; Hu H; Pyon V; Thakurdin C; Papadopoulos E; Tang S; Gonzalvez F; Chen H; Rivera VM; Brake R; Vincent S; Wong KK
    Cancer Res; 2021 Oct; 81(20):5311-5324. PubMed ID: 34380634
    [TBL] [Abstract][Full Text] [Related]  

  • 54. HER2 and lung cancer.
    Landi L; Cappuzzo F
    Expert Rev Anticancer Ther; 2013 Oct; 13(10):1219-28. PubMed ID: 24134423
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Molecular characteristics and prognostic factors of leptomeningeal metastasis in non-small cell lung cancer.
    Liu X; Li G; Zhang H; Chang Q; Fang M; Lu C; Tian P; Mei F
    Clin Neurol Neurosurg; 2023 Feb; 225():107572. PubMed ID: 36610238
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
    Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ
    Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The presence of HER2 exon 20 insertion in patients with central nervous system metastases from non-small lung cancer--a potential application in classification for therapy.
    Nicoś M; Krawczyk P; Mlak R; Sawicki M; Jarosz B; Powrózek T; Milanowski P; Trojanowski T; Milanowski J
    Pneumonol Alergol Pol; 2013; 81(4):294-7. PubMed ID: 23744164
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Genetic screening and molecular characterization of MET alterations in non-small cell lung cancer.
    Saigi M; McLeer-Florin A; Pros E; Nadal E; Brambilla E; Sanchez-Cespedes M
    Clin Transl Oncol; 2018 Jul; 20(7):881-888. PubMed ID: 29139039
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non-Small-Cell Lung Cancer.
    Sacher AG; Dahlberg SE; Heng J; Mach S; Jänne PA; Oxnard GR
    JAMA Oncol; 2016 Mar; 2(3):313-20. PubMed ID: 26720421
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.
    Yao ZH; Liao WY; Ho CC; Chen KY; Shih JY; Chen JS; Lin ZZ; Lin CC; Chih-Hsin Yang J; Yu CJ
    Oncologist; 2017 Sep; 22(9):1075-1083. PubMed ID: 28507206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.